AAN: American Academy of Neurology
American Academy of Neurology (AAN): Annual Meeting
Conference Coverage
Boxing helps knock out nonmotor symptoms of Parkinson’s disease
Noncontact boxing improved nonmotor symptoms such as fatigue, depression, and anxiety, and had a significant effect on quality of life.
Conference Coverage
Ping-pong may improve motor symptoms in patients with Parkinson’s disease
The rehabilitative intervention can beneficial, especially during the early stages of the disease.
Conference Coverage
Excessive sleepiness linked to heart disease, cancer, and diabetes
“Paying attention to sleepiness in older adults could help doctors predict and prevent future medical conditions.”
Conference Coverage
A healthy heart in youth protects the brain later on
“What is good for the heart is also good for the brain.”
Conference Coverage
New gene variants linked to tau deposits in Alzheimer’s disease
New genetic insights may better predict who may become symptomatic from the disease and help develop targets for treatment.
Conference Coverage
Blue light improves concussion symptoms
Blue light in the morning may help reset the circadian rhythm in people who have suffered a concussion.
Conference Coverage
American Academy of Neurology cancels annual meeting amid COVID-19 pandemic
The AAN's annual meeting, scheduled for April 25-May 1, 2020, in Toronto has become the latest medical conference casualty of the COVID-19...
Medical Education Library
MS Highlights From the AAN & CMSC Annual Meetings
Conference Coverage
Tranexamic acid may not improve neurologic outcomes in patients with TBI
PHILADELPHIA – Administration of a 2-gram bolus of tranexamic acid to a patient with both TBI and ICH may improve 28...
Conference Coverage
Imaging predicts early postural instability in Parkinson’s disease
PHILADELPHIA – Using imaging and clinical data, researchers developed a seven-item scale to identify patients with...
Conference Coverage
Mutant huntingtin and neurofilament light are potential biomarkers in Huntington’s disease
PHILADELPHIA – The biomarkers successfully distinguish between healthy controls, patients with premanifest disease,...
Conference Coverage
Evobrutinib demonstrates efficacy, safety in relapsing MS
PHILADELPHIA – Primary endpoint of reducing enhancing lesions versus placebo was met with evobrutinib.
Conference Coverage
Fingolimod reduced disease activity more than glatiramer acetate in RRMS: ASSESS study results
PHILADELPHIA – Relapse rate and radiographic endpoints significantly improved with the 0.5-mg daily dose of fingolimod, with safety as expected...
Conference Coverage
Ocrelizumab effective, safe in relapsing-remitting MS patients
PHILADELPHIA - A positive risk-to-benefit ratio over nearly 1 year for the anti-CD20 monoclonal antibody.
Conference Coverage
Deutetrabenazine benefit may increase over time in patients with tardive dyskinesia
PHILADELPHIA – Interim results of an open-label study suggest that changes in AIMS score are at least maintained over the course of nearly 3 years...